Shape Therapeutics, Inc. is the latest gene therapy-focused company to raise a large amount of capital with the aim of developing adeno-associated viral (AAV) vector-based gene therapies that offer improvements over existing products.
Seattle-based ShapeTx said on 15 July that it completed a $112m series B venture capital round, which it plans to...






